Please assess the completion status of the following clinical trial:

Trial Title: Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have given written informed consent (signed and dated) and any authorizations required by local law~2. 18 to 75 years old (inclusive)~3. Male or female with a diagnosis of PBC, by at least two of the following criteria:~   * History of AP above ULN for at least six months~  * Positive AMA titers (\>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies~  * Documented liver biopsy result consistent with PBC~4. On a stable and recommended dose of UDCA for the past twelve months or intolerant to UDCA~5. AP ≥ 1.67 × ULN~6. Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose~Exclusion Criteria:~1. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)~2. AST or ALT \> 3 × ULN~3. Total bilirubin \> 2.0 mg/dL~4. Total bilirubin \> ULN AND albumin \< LLN with the exception to subjects with Gilbert's Syndrome. Subjects with Gilbert's syndrome are excluded if Direct Bilirubin \> ULN.~5. Auto-immune hepatitis~6. Primary sclerosing cholangitis~7. Known history of alpha-1-Antitrypsin deficiency~8. Known history of chronic viral hepatitis~9. Creatine kinase above ULN~10. Serum creatinine above ULN~11. For females, pregnancy or breast-feeding~12. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months preceding screening~13. Current use of fibrates or simvastatin~14. Current use of obeticholic acid~15. Use of an experimental or unapproved treatment for PBC~16. Use of experimental or unapproved immunosuppressant~17. Adverse event leading to MBX-8025 discontinuation from CymaBay's phase 2 PBC study (CB8025-21528)~18. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MBX-8025 (2 mg) (Type: EXPERIMENTAL): MBX-8025 2 mg capsule once daily
- MBX-8025 (5 mg) (Type: EXPERIMENTAL): MBX-8025 5 mg capsule once daily
- MBX-8025 (10 mg) (Type: EXPERIMENTAL): MBX-8025 10 mg capsule once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).